Table 1.
Characteristics of patients in the study (n = 20).
| AI arm (n = 10) | Non-AI arm (n = 10) | |
|---|---|---|
| Age | 67 ± 13 | 56 ± 17 |
| Sex (female) | 2 (20%) | 2 (20%) |
| Weight (kg) | 55.9 ± 9.6 | 52.4 ± 14.0 |
| Height (cm) | 163.2 ± 7.0 | 161.3 ± 6.8 |
| BMI (kg/m2) | 20.9 ± 2.4 | 20.0 ± 5.0 |
| Comorbidities (1 or more) | 6 (60%) | 4 (40%) |
| Hypertension | 6 (60%) | 4 (40%) |
| Diabetes | 1 (10%) | 0 (0%) |
| Others (Chronic liver disease, arthritis) | 1 (10%) | 1 (10%) |
| Sedative use during ICU | 10 (100%) | 10 (100%) |
| Use of non-depoplarising neuromuscular blocking agents during ICU stay | 10 (100%) | 10 (100%) |
| Length of ICU stay (days) | 26 ± 11 | 24 ± 5 |
| Length of hospital stay (days) | 32 ± 13 | 31 ± 6 |
| Mechanical ventilation duration (days) | 19.7 ± 8.2 | 17.8 ± 5.5 |
| ANSD duration (days) | 12.4 ± 6.7 | 12.0 ± 2.8 |
| Total dose of Pipecuronium | 438 ± 190 | 430 ± 250 |
| Enteral nutrition | 10 (100%) | 10 (100%) |
| Rehabilitation duration (days) | 10 ± 9 | 8 ± 4 |
| HAI during ICU stay | 8 (80%) | 9 (90%) |
| RF CSA D1 (cm2) | 4.37 ± 1.08 | 4.76 ± 1.50 |
| RF CSA D7 (cm2) | 4.09 ± 1.01 | 4.51 ± 1.59 |
| RFCSA Discharge (cm2) | 3.25 ± 1.24 | 3.65 ± 1.15 |
| % change in RFCSA during ICU stay (%) | 26 ± 15 | 23 ± 11 |
| ICU survival | 10 (100%) | 10 (100%) |
BMI body mass index, MV mechanical ventilation, ANSD autonomous nervous system dysfunction, HAIs hospital-acquired infections, RFCSA D1 rectus femoris cross sectional area on ICU admission, RFCSA D7 rectus femoris cross sectional area on day 7, RFCSA Discharge rectus femoris cross sectional area at ICU discharge.